Human epidermal growth factor receptor 2-positive breast cancer relapsing post-adjuvant trastuzumab: Pattern of recurrence, treatment and outcome

Clinical Breast Cancer

Volumn 11, Issue 3, 2011, Pages 153-160

  Krell, Jonathan ^a   James, Colin R ^b   Shah, Deep ^a   Gojis, Ondrej ^a,c   Lim, Adrian ^a   Riddle, Pippa ^a   Ahmad, Riz ^a   Makris, Andreas ^d   Cowdray, Andrew ^a   Chow, Angela ^a   Babayev, Tamerlan ^a   Madden, Peter ^a   Leonard, Robert ^a   Cleator, Susan ^a   Palmieri, Carlo ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c CHARLES UNIVERSITY   (Czech Republic)

^d MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

Breast cancer; Relapse; Response; Trastuzumab

Indexed keywords

ANASTROZOLE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GOSERELIN; NAVELBINE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN CELL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOLOGY; PATIENT ASSESSMENT; TREATMENT DURATION; TREATMENT RESPONSE; ADULT; AGED; BREAST TUMOR; CHEMISTRY; DISEASE FREE SURVIVAL; MIDDLE AGED; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 80053402731     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2011.03.012     Document Type: Article

References (27)

1. Taucher S, Rudas M, Mader RM, et al. Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer. Wien Klin Wochenschr 2004; 116:26-31. (Pubitemid 38313560)
2. Arnedos M, Nerurkar A, Osin P, et al. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol 2009; 20:1948-52.
3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2-2/neu oncogene. Science 1987; 235: 177-82. (Pubitemid 17231334)
4. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 34:791-808. (Pubitemid 28248487)
5. Kallioniemi OP, Kallioniemi A, Kurisu W, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 1992; 89:5321-5.
6. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92. (Pubitemid 32222155)
7. Slamon D, Eiermann W, Robert N, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat, 2005; 94:S5 (suppl 1; abstract 1).
8. Piccart-Gebhart M, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-72. (Pubitemid 41464705)
9. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-84. (Pubitemid 41464706)
10. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354:809-20. (Pubitemid 43290919)
11. Spielmann M, Roché H, Delozier T, et al. Trastuzumab for patients with axillarynode-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009; 27:6129-34.
12. Fisher B, Bryant J, Wolmark N. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672-85. (Pubitemid 28363030)
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-16. (Pubitemid 30099779)
14. Mariani G, Fasolo A, De Benedictis E, et al. Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 2009; 6:93-104.
15. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14:2738-46. (Pubitemid 26329660)
16. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13:4429-34. (Pubitemid 47219710)
17. Mansell J, Monypenny IJ, Skene AI, et al. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat 2009; 117:91-8.
18. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009; 15:7479-91.
19. Mittendorf EA, Wu Y, Scaltriti M, et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009; 15:7381-8.
20. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007; 13:228-33. (Pubitemid 46121873)
21. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by AT versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (theNOAHtrial): a randomized controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375:377-84.
22. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009; 27:5278-86.
23. Pegram MD, Lopez A, Konecny G, et al. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 2000; 27:21-5. (Pubitemid 32172252)
24. Palmieri C, Krell J, James CR, et al. Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat Rev Clin Oncol 2010; 7:561-74.
25. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733-43. (Pubitemid 46021510)
26. Von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advnaced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol 2009; 27:1999-2006.
27. Sharma A, Crook T, Thompson A, et al. Surgical oncology: why biopsying metastatic breast cancer should be routine. Nat Rev Clin Oncol 2010; 7:72-4.